CD86
T-lymphocyte activation antigen CD86
As of the edition of 20 October 2026, CD86 (T-lymphocyte activation antigen CD86, UniProt P42081) has 2 drugs tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P42081
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Nervous system; Heart and blood vessels
- Registered trials of its drugs
- 225
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Abatacept | Marketed | Phase 4 | Ends 2028 |
| Belatacept | Marketed | Phase 4 | Ended 2023 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |